I saw this website though Google News, regarding about the Society for Neuro-Oncology (SNO) 15th Anniversary.
December 1, 2010 (Montreal, Quebec) — A large study of patients with newly diagnosed glioblastoma multiforme suggests that the addition of 2 agents — bevacizumab and irinotecan — to standard chemoradiation can extend survival, compared with historic controls.
Of course, at least one doctor is upset about the fact that this study is too wide.
"It's flatly outrageous. It should not have been done," he said in an interview with Medscape Medical News after the session. Dr. van den Bent is past chair of the European Organization of Research and Treatment Brain Tumor Group, and professor of neuro-oncology at the Daniel den Hoed Cancer Center, Erasmus University, in Rotterdam, the Netherlands.
I guess I'm most curious about this is, it's always about newly diagnosed patients. With the combination of Irinotecan and Avastin, it is also new for me, as well, but I'm no longer one of the most recent patients who are hoping to extend to 20 months. I'm just starting to add Irinotecan after two and a half years with a (still) great success with Avastin, and for a long time, Tarceva (no longer working, hence the need to start with Irinotecan).
I have another MRI with Dr. Rudnick on December 15, 2010, after I have a third infusion at Dr. Nassir's clinic on Tuesday. Rudnick told Dana and I that the next MRI results might be too soon to truly know if we're see good improvement with this new spot. I'm kind of irritated that I didn't go to imaging center at Cedars after I had the MRI and pick-up a CD. I'll definitely be doing that this time, because I had actually get both of those scans, and see if there's a clear difference.
lee
_____________________________________
Band: This Will Destroy You
Track: Threads
Download 03 Threads
Recent Comments